SecondWave Systems, Inc. is a pioneering company in the field of bio-ultrasonic medicine, developing a noninvasive, wearable ultrasound stimulation platform. Founded in 2019 by Anuj Bhardwaj, Jeff Heyman, and Hubert Lim, the company aims to offer new treatment options for debilitating diseases like rheumatoid arthritis (RA). Headquartered in Minneapolis, Minnesota, SecondWave Systems has secured funding of over $15 million from U.S. government agencies to advance its innovative technology.
Attribute | Information |
---|---|
Founding Date | 2019 |
Headquarters | Minneapolis, MN, USA |
Founders | Anuj Bhardwaj, Jeff Heyman, Hubert Lim |
Key Investors | ARPA-H, DARPA |
Industry | Bio-Ultrasonic Medicine |
Number of Employees | 11-50 |
SecondWave Systems was conceived from the ideas and leadership of Anuj Bhardwaj, inspired by ultrasonic equipment used in industrial settings. In 2018, Bhardwaj, along with Jeff Heyman and Hubert Lim, explored the potential of low-intensity focused ultrasound (LiFU) in medicine. The early focus was on targeting the spleen to treat rheumatoid arthritis by reducing inflammation—a breakthrough that attracted funding and partnerships with institutions like the University of Minnesota and DARPA.
SecondWave Systems has emerged as a leader in bio-ultrasonic technology by developing the MINI platform, a wearable device for noninvasive treatment. Key achievements include successful pilots exhibiting significant patient improvement in RA and strategic collaborations with key medical institutions and government entities. The company's device operates by modulating the spleen to control inflammation. SecondWave's progress is bolstered by multiple rounds of funding and a robust IP portfolio anticipated to expand its application across various clinical conditions.
Currently, SecondWave Systems is advancing its MINI platform to full commercialization. With strong support from government agencies and affiliations with research institutions, it positions itself as a significant player in the noninvasive therapy market. The company's unique approach through LiFU technology provides an alternative to conventional medication, potentially decreasing long-term healthcare costs and improving patient outcomes in inflammation-related conditions.
SecondWave Systems stands at the forefront of bio-ultrasonic medicine, offering innovative noninvasive treatment options with its MINI platform. Positioned with substantial government support and strategic partnerships, it has the potential to redefine standards in managing chronic inflammatory diseases like RA. With ongoing clinical trials and market expansion, SecondWave aims to continue its trajectory towards becoming a pivotal entity in healthcare innovation.